Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

703.16
+13.581.97%
Number of Gainers:47
Number of Losers:95
Number of Flat:11
PE:- -
High:707.24
Open:689.67
Low:689.64
Close:689.58
Volume:499.41M
Turnover:18.06B
Market Cap:485.23B
Float Cap:369.77B

Loading ...

Aurora Networks, Vistance Networks Unit, Deploys Kaltura Cloud TV Platform at Bouygues Telecom

Reuters
·
Sep 08

Robinhood Strikes Deal with Crypto.com in Latest Prediction-Markets Push- WSJ

THOMSON REUTERS
·
Sep 08

Robinhood Will Add Yes-or-no Contracts from Crypto.com Prediction Business and Take Stake in Digital-Currency Exchange- WSJ

THOMSON REUTERS
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Upexi to Participate in FT Partners FinTech Conference 2026 on September 15th

GlobeNewswire
·
Sep 08

Rani Therapeutics to Participate in Upcoming September Conferences

GlobeNewswire
·
Sep 08

Climb Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 08

Analysts Offer Insights on Technology Companies: Shopify (SHOP) and UiPath (PATH)

TIPRANKS
·
Sep 08

Robinhood Markets Price Target Raised to $150.00/Share from $115.00 by Cantor Fitzgerald

Dow Jones
·
Sep 08

Absci price target raised to $15 from $13 at BTIG

TIPRANKS
·
Sep 08

Monte Rosa Therapeutics to receive $50M milestone payment from Novartis

TIPRANKS
·
Sep 08

Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone

Reuters
·
Sep 08

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Novartis to Fund Phase 2; Monte Rosa to Co-Fund Phase 3 and Share 30% U.S. Profits/Losses

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for up to $2.10 Bln in Milestones Starting with Phase 2 Initiation

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - to Receive $50 Mln Milestone Payment from Novartis for First Patient Visit

THOMSON REUTERS
·
Sep 08

Absci Price Target Raised to $16.00/Share from $13.00 by BTIG

Dow Jones
·
Sep 08

AppLovin Price Target Cut to $396.00/Share from $408.00 by BTIG

Dow Jones
·
Sep 08

UiPath initiated with a Buy at Citi

TIPRANKS
·
Sep 08